Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while Recursion Pharmaceuticals Inc trades at $3.04 (market cap $1.53B). The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| JPIN | RXRX | |
|---|---|---|
52-Week High | $76.96 | $6.79 |
52-Week Low | $63.14 | $2.84 |
Market Cap | — | $1.53B |
Sector | — | Health |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
